ORYZON presents positive efficacy results on iadademstat in ED-SCLC patients at ESMO-2019

by Oryzon Genomics

5 years ago
iadademstat, lung cancer, hematology

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical needs, announc...

ORYZON’s iadademstat shows efficacy signs in relapsed SCLC

by Oryzon Genomics

5 years ago
iadademstat, cancer, lung, CLEPSIDRA

ORYZON Announces End of Patient Recruitment for its Phase IIa trials in aggression with vafidemstat: REIMAGINE and REIMAGINE-AD

by Oryzon Genomics

5 years ago
ORYZON, trials, patient, REIMAGINE, REIMAGINE-AD, psychiatric disorders, Alzheimer

ORYZON ha presentado datos de ETHERAL: un ensayo clínico de Fase IIa con vafidemstat en Enfermedad de Alzheimer en la Conferencia Internacional de la Asociación de Alzheimer (AAIC) en Los Ángeles, EE.UU.

by Oryzon Genomics

5 years ago
Oryzon Genomics, vafidemstat, alzheimer

Oryzon Genomics, S.A., compañía biofarmacéutica de fase clínica centrada en la epigenética para el desarrollo de terapias en enfermedades con importantes necesidades médicas no resueltas, presen...

ORYZON to present data from ETHERAL Phase IIa trial at the 2019 Alzheimer's Association International Conference in Los Angeles

by Oryzon Genomics

5 years ago
ETHERAL, clinical trial, Alzheimer, epigenetics

Oryzon Genomics, S.A.(ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced...

ORYZON anuncia el reclutamiento en EE.UU. del Primer Paciente en ETHERAL-US: un ensayo clínico de Fase IIa con vafidemstat en Enfermedad de Alzheimer

by Oryzon Genomics

5 years ago
ETHERAL-US, ensayo clínico, Vafidemstat, Alzheimer, biomarcadores, fármaco

En Europa el reclutamiento ya ha sobrepasado los 100 pacientes

ORYZON Receives $1.5 million grant from Alzheimer’s Drug Discovery Foundation (ADDF)

by Oryzon Genomics

5 years ago
help fund, ADDF, Alzheimer’s Drug, Oryzon

Proceeds to help fund ETHERAL-US Phase IIa examing vafidemstat in Alzheimer’s disease. ADDF stake in the company represents 0.94% of the common stock.

Oryzon presente en conferencias de reconocido prestigio internacional

by Oryzon Genomics

5 years ago
Oryzon, conferencias, prestigio

ORYZON presenta nuevos resultados de eficacia en pacientes tratados con vafidemstat en el 7º Congreso Mundial de Trastorno por Déficit de atención e Hiperactividad (TDAH) en Lisboa

by Oryzon Genomics

5 years ago
epigenética, biofármaco, congreso, TDHA, vafidemstat, agresividad

Oryzon presenta hoy sus primeros resultados de eficacia en pacientes tratados con Vafidemstat en el 27º Congreso Europeo de Psiquiatría en Varsovia

by Oryzon Genomics

5 years ago
Oryzon, Vafidemstat, Congreso, epigenética, TLP, ASD, TDAH, Vall d'Hebron

ORYZON Announces Publication of a relevant paper for the therapeutic development of Iadademstat (ORY-1001) in Small Cell Lung Cancer (SCLC)

by Oryzon Genomics

5 years ago
ORYZON, Iadademstat, publication, antitumor drug, Lung cancer

Complete and durable tumor regression occurred with Iadademstat–induced NOTCH activation in a chemoresistant PDX model. Further supports LSD1 inhibitors as a possible new and targeted therapy for SC...

Oryzon announces First-Patients-in in CLEPSIDRA: a Phase IIa clinical trial with Iadademstat (ORY-1001) in Small Cell Lung Cancer patients

by Oryzon Genomics

5 years ago
epigenetics, therapies, serious diseases, treatments, patients, ORY-1001, small cell lung cancer, SCLC, CLEPSIDRA

Oryzon Genomics has announced today the inclusion of the first two p atient s in a Phase IIa clinical study with Iadademstat (ORY - 1001) in Small Cell Lung Cancer (SCLC) patients .